Intrinsic Imaging Awarded Medical Device Trial for Percutaneous Tumor Ablation

Boston, MA — April 23, 2015 — Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant medical imaging core lab specializing in providing services for clinical trials, announced today that it has been awarded a clinical trial to study an interventional medical device designed for the percutaneous ablation of cancerous tumors.

Intrinsic Imaging will provide comprehensive imaging core lab services. As the evaluation of loco-regional ablative techniques requires significant expertise in multimodal ablation zone evaluation, Intrinsic Imaging's board-certified fellowship-trained interventional radiologists will also provide guidance to the Sponsor on the imaging charter, optimal image acquisition parameters and the most reliable and reproducible imaging endpoints to assess pre- and post-tumor ablation findings.

Image-guided percutaneous tumor ablation is a technique of controlled, direct destruction of cells and tissue with the end goal of complete tumor destruction. Ablative therapy can be performed for both primary and metastatic tumors. The spectrum of ablation therapies encompasses techniques such as radiofrequency ablation (RFA), cryoablation, laser ablation, microwave ablation, high-intensity focused ultrasound, and irreversible electroporation.